Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D82BZH
|
|||
| Drug Name |
Ozuriftamab vedotin
|
|||
| Synonyms |
BA3021
Click to Show/Hide
|
|||
| Drug Type |
Antibody drug conjugate
|
|||
| Indication | Head-neck squamous cell carcinoma [ICD-11: 2D60.0; ICD-10: C77.0] | Phase 2 | [1] | |
| Company |
BioAlta
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Neurotrophic tyrosine kinase ROR2 (ROR2) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Wnt signaling pathway | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05271604) A Phase 2 Open-Label Study of Ozuriftamab Vedotin (BA3021) in PD-1/L1 Failure Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. U.S.National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of BioAtla | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.